Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

8.480 +0.230 (+2.79%)
Delayed Quote Updated: 3:31 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Where Puma Biotechnology Stands With Analysts ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock ↗
 
Via Benzinga
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Third Quarter 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Join Russell 3000 Index
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute ↗
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment. 
Via Benzinga
Topics Intellectual Property
News headline image
PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024 ↗
PBYI stock results show that Puma Biotechnology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Puma Biotechnology Reports First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
7 Stocks Under $15 Predicted to Boom in the Next 2 Years ↗
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.